FDA Backs Celltrion Biosimilar Of Janssen's Remicade
The U.S. Food and Drug Administration on Tuesday approved Celltrion's biosimilar Inflectra, a copy of Janssen Biotech's immunosuppressant Remicade that is the second and most complex biosimilar cleared in the U.S....To view the full article, register now.
Already a subscriber? Click here to view full article